BioSpace News Archive

KalVista Pharmaceuticals, Inc. today announced data presented for its oral drug candidates at the European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company’s upcoming contributions to the 11 th International AIDS Society (IAS) Conference on HIV Science, taking place virtually from July 18-21.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced new preclinical data demonstrating the therapeutic potential of its STAT3 degraders for the treatment of peripheral T-cell lymphoma (PTCL) with aberrant STAT3 activation.

OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA.

Amedisys, Inc., a leading provider of home health, hospice and personal care, will report results for the second quarter ended June 30, 2021, after the market closes on August 4, 2021.

First-in-human open label Phase 1 study of INKmune will assess safety and tolerability and multiple measures of clinical activity and response in high-risk MDS patients

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced three oral presentations demonstrating the potential clinical utility of ibrexafungerp at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Allena Pharmaceuticals, Inc. provided progress updates on its clinical programs: ALLN-346, a first-in-class, oral urate degrading enzyme in development for the treatment of patients with hyperuricemia and gout in the setting of chronic kidney disease and reloxaliase, a first-in-class, oral oxalate degrading enzyme in development for the treatment of patients with enteric hyperoxaluria.

Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), the Company developing new classes of synthetic anti-infectives is pleased to announce multiple patients have been dosed with RECCE® 327 (R327) in a topical Phase I/II clinical trial at the Fiona Stanley Hospital Burns Unit in Perth, Western Australia

Eargo, Inc. today applauded the Biden Administration’s July 9, 2021 Executive Order on Promoting Competition in the American Economy, which directs the Department of Health and Human Services to consider issuing proposed rules within 120 days for allowing hearing aids to be sold over the counter (OTC).